Related Experiment Video
Updated: Nov 7, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation in a Patient With Mechanical Prosthetic Valves and Calcific Uremic Arteriolopathy on Warfarin
Megan C Smith1, Evan Gleaves2, Aniruddha Singh1
1Cardiology, University of Kentucky, Bowling Green, USA.
Insights
Calciphylaxis (or calcific uremic arteriolopathy) is a rare vascular disease causing painful skin lesions, often in end-stage renal disease patients. Managing anticoagulation in these patients with mechanical valves presents unique challenges due to limited guidelines.
Area of Science:
- Nephrology
- Vascular Medicine
- Dermatology
Background:
- Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare and severe vascular calcification disorder.
- It is frequently linked to chronic kidney disease, particularly end-stage renal disease (ESRD), and warfarin use.
Observation:
- This report details a case of CUA in a Caucasian female with a history of nephrogenic systemic fibrosis (NSF), ESRD, and mechanical heart valves.
- The patient was anticoagulated with warfarin and developed characteristic painful skin lesions progressing to ulceration.
Findings:
- The case highlights the complex management of anticoagulation in patients with mechanical prosthetic valves.
- Vitamin K antagonists (VKAs) and aspirin are the primary evidence-based antithrombotic options in this population.
Implications:
- This case underscores the challenges in anticoagulant therapy decision-making for CUA patients with mechanical valves, especially when established guidelines are lacking.
- Further research is needed to develop clear management strategies for this high-risk patient group.
Abstract:
Calciphylaxis, or calcific uremic arteriolopathy (CUA), is a rare vascular calcific disease that is most often associated with renal dysfunction and warfarin, particularly end-stage renal disease (ESRD). This condition causes debilitatingly painful skin lesions, oftentimes plaques, throughout areas of cutaneous and subcutaneous adiposity. The progression of these lesions to black eschar with ulceration is the hallmark of CUA. In this report, we present the case of a Caucasian female with a past medical history of nephrogenic systemic fibrosis (NSF), ESRD, and mechanical aortic and mitral valves, anticoagulated with warfarin, who developed CUA. In the setting of mechanical prosthetic valves, vitamin K antagonists (VKA) and aspirin are the only evidence-based antithrombotic therapies. This case presents challenging decision-making when managing anticoagulant therapy in the absence of applicable guidelines.
More Related Videos
05:47Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
Published on: May 10, 2021
04:30Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:30Venous Thrombosis IV: Nursing Management
01:25Aortic Regurgitation III: Medical Management
01:27Peripheral Artery Disease III: Interprofessional Care